Clinical Recommendations: Tobacco Dependence Syndrome, Tobacco Withdrawal Syndrome in Adults

Objectives

Provide evidence-based clinical support for adults with tobacco dependence and tobacco-withdrawal syndrome, including nicotine dependence and smoking-related respiratory manifestations, with the primary treatment objective of achieving sustained abstinence from tobacco products for at least six months.[1][2][3]The recommendations frame tobacco smoking as a major preventable cause of disease, premature death and reduced quality of life, affecting multiple organ systems and contributing particularly to cancer, cardiovascular and respiratory disease.[4][5][6]

• Identify tobacco dependence through recognised diagnostic symptoms, including craving, impaired control, withdrawal, tolerance, prioritisation of tobacco use and continued use despite harm; dependence is identified when at least three defined symptoms occur within 12 months.[7][8]
• Assess tobacco withdrawal after partial or complete cessation, including craving, malaise, dysphoria, irritability, insomnia, increased appetite, cough and impaired concentration, recognising that symptom intensity may contribute to relapse.[8][9][10][11]
• Reduce nicotine dependence and strengthen motivation to stop through behavioural support, pharmacological treatment where appropriate, and management of withdrawal symptoms.[2][12][13]
• Address respiratory complications associated with smoking and cessation, including cough, sputum production, dyspnoea, bronchial hyperreactivity and bronchial obstruction.[14][15][16]
• Promote complete cessation rather than lower-risk tobacco use, noting that low-tar and low-nicotine cigarettes do not remove the risks of lung cancer and other smoking-related diseases.[4][5]
• Protect household members, especially children, from second-hand smoke and encourage smoke-free homes and cars.[17][18]
• Provide enhanced cessation support for pregnant women and ensure that patients with mental disorders receive care from a psychiatrist-narcologist or psychiatrist.[19][20]

Implementation

Use a staged, individualised clinical pathway combining assessment, brief intervention, motivational and behavioural support, pharmacotherapy, respiratory management and follow-up.[21]The material does not set out a programme budget or a population-level delivery system, but it identifies a multidisciplinary clinical audience and grounds the recommendations in Russian health legislation, care standards and graded evidence review.[22][23][24]

• Assess tobacco exposure and dependence by taking a smoking history, calculating the smoking index, applying the Fagerström test, assessing readiness through the Prochaska questionnaire, and recording results in medical documentation.[25][26][2]
• Measure exhaled carbon monoxide for all patients to estimate smoking intensity, support motivation to quit and monitor cessation progress; readings of 6–10 parts per million indicate mild smoking, 11–20 moderate smoking and more than 21 heavy smoking.[25][27]
• Evaluate respiratory symptoms and lung function using spirometry, peak-flow measurement and bronchodilator testing where indicated, including assessment of reversibility and bronchial obstruction.[27][28]
• Deliver a brief intervention of at least three minutes through physicians of all specialities and mid-level medical personnel, determining smoking status, giving personalised cessation advice and identifying suitable assistance.[12]
• Apply the 5A model, Ask, Advise, Assess, Assist and Arrange, for patients who smoke, and use the 5R model, Relevance, Risks, Rewards, Roadblocks and Repetition, to build motivation among people not ready to quit.[29][30][31]
• Provide behavioural therapy throughout treatment, initially with more frequent sessions and later monthly support, addressing triggers, coping skills, relapse prevention and the patient’s immediate social environment.[31][32]
• Tailor nicotine-replacement therapy to dependence severity, cigarette consumption, withdrawal symptoms and preferred formulation; available options include patches, gum, sublingual tablets and oral spray, used alone or in combination.[33][34]
• Use nicotine-replacement therapy for a usual course of three to six months, with extension up to 12 months for very high dependence where needed; adjust or combine products when withdrawal symptoms remain uncontrolled.[34][35][36]
• Support a reduction-before-cessation pathway for people with low motivation, but keep the reduction period short, preferably no longer than six weeks, before a planned quit date and complete cessation.[37][38]
• Consider non-nicotine partial nicotinic-receptor agonists, including varenicline and cytisine; the cited material distinguishes evidence supporting varenicline from the absence of demonstrated six-month abstinence effectiveness for cytisine.[39][40]
• Use anxiolytics as adjuncts where anxiety, restlessness or irritability persist, avoid antidepressants for nicotine dependence because of insufficient demonstrated effectiveness and serious adverse effects, and consider reflexotherapy only as an additional intervention for withdrawal symptoms.[41][42]
• Manage cough and sputum with mucolytic or expectorant medicines and use bronchodilators where bronchial hyperreactivity or obstruction is identified, selecting short-acting or prolonged-acting treatment according to clinical severity.[43][44][45]
• Monitor treatment principally through withdrawal control, medicine use, craving response and maintenance of tobacco abstinence for at least six months; the source also identifies 12 clinical quality criteria for diagnosis and treatment, although it does not specify broader reporting, surveillance or accountability arrangements.[3][46][21]
• Maintain evidence governance through graded recommendations based on research quality and update the clinical recommendations every three years.[47][23]

Monitoring & Evaluation

Monitoring is primarily clinical and treatment-focused rather than a population-level performance or accountability framework. Assessment covers tobacco-use status, nicotine-dependence severity, readiness to quit, withdrawal symptoms, smoking exposure, exhaled carbon monoxide, and respiratory function where bronchial disease is suspected.[48][26][21]A representative 2016 Global Adult Tobacco Survey directed by the Ministry of Health of the Russian Federation provides the principal population-level evidence cited, including indicators on current tobacco use, daily smoking, cigarette consumption, age at initiation, time to first cigarette, and electronic-cigarette use.[49][50]

• Assess tobacco dependence through symptom-based diagnostic criteria, with dependence identified when at least three specified symptoms occur over a 12-month period.[7][8]
• Classify nicotine-dependence severity using the Fagerström test, and use the Prochaska questionnaire to assess motivation and readiness to stop tobacco use.[51][26][52]
• Record dependence-test results in medical documentation and document brief interventions, including smoking status and cessation support provided.[2][12][53]
• Measure exhaled carbon monoxide for all patients to estimate smoking intensity, strengthen motivation to quit, and monitor cessation progress during treatment.[25][27]Readings of 6–10 parts per million indicate mild smoking, 11–20 moderate smoking, and above 21 heavy smoking.[27]
• Assess lung function through spirometry, peak-flow measurement and bronchodilator testing when respiratory symptoms, bronchial hyper-responsiveness or bronchial obstruction are relevant.[27][28]Reversible obstruction is indicated by a post-bronchodilator forced expiratory volume in one second increase of at least 12% or 200 millilitres.[28]
• Monitor withdrawal symptoms, cravings and treatment use to adjust nicotine-replacement therapy.[34][46][54][37]For nicotine gum or tablets, progressively reduce daily use after symptoms are controlled and discontinue when use reaches one or two units per day.[55][35][36]
• Evaluate cessation treatment principally against maintenance of tobacco abstinence for at least six months.[3]The source also notes that the maximum reduction of withdrawal symptoms is a key criterion for nicotine-replacement treatment.[46]
• Arrange follow-up visits, provide repeated motivational discussions at healthcare contacts, deliver behavioural therapy throughout treatment, and offer post-treatment counselling to prevent relapse.[29][31][32]Behavioural therapy is described as lasting three to six months, initially weekly and then less frequently.[32]
• Monitor implementation against 12 clinical quality criteria covering diagnosis and treatment, including smoking index calculation, dependence and motivation assessment, carbon-monoxide measurement, behavioural support, pharmacotherapy, and management of withdrawal and respiratory symptoms.[21]
• Apply evidence and recommendation grading to clinical interventions, with evidence levels ranging from 1a meta-analyses of randomised controlled trials to level 4 expert consensus, and recommendation grades from A to C.[47]Update the clinical recommendations every three years.[47][23]

Formal programme-level reporting schedules, quantitative targets, routine surveillance plans, institutional accountability arrangements and evaluation timetables are generally not specified beyond patient-record documentation, clinical quality criteria, evidence grading and the cited tobacco survey.[12][53][21][47][23]

Costing & Financing

The source provides no explicit programme costing, treatment prices, budgets, expenditure allocations, financing sources, resource-mobilisation arrangements, funding gaps or economic assumptions for tobacco-dependence diagnosis, cessation support or respiratory treatment.[2][56][21][47]It identifies clinical resource inputs, including trained healthcare personnel, counselling, diagnostic testing, nicotine-replacement products, pharmacotherapy and respiratory medicines, but does not attach monetary values to these inputs.[25][33][12][21]

• Provide cessation support through brief interventions by physicians of all specialities and mid-level medical personnel, with referral where appropriate care is unavailable.[12][53]
• Use diagnostic resources including carbon-monoxide measurement, spirometry, peak-flow assessment and bronchodilator testing where clinically indicated.[25][27][28]
• Supply treatment options including nicotine-replacement products, varenicline, behavioural therapy, motivational counselling, anxiolytics in specified circumstances, and medicines for respiratory symptoms or obstruction.[33][41][43][21]
• Recognise possible household savings from no longer purchasing cigarettes and related smoking products, although no financial estimate is provided.[17]

No machine-readable cost values can be extracted because the supplied material contains no explicit monetary amounts, currencies, budget periods or quantified funding gaps.[2][21][24]